International Clinical Trial: A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121742) titled 'A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors' on April 2.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute)

Condition: Advanced Solid Tumors

Intervention: Phase 1a Monotherapy Dose Escalation:BG-C477 intravenous infusion with dose escalation, starting at 1.5 mg/kg every 3 weeks Phase...